NCT03179371

Brief Summary

Congenital diaphragmatic hernia (CDH) is a severe congenital malformation, related to a developmental defect of the diaphragm. The incidence of CDH is approximated at 1 in 3,000 live births. Although advances in surgery and neonatal intensive care have improved the prognosis, mortality remains high, around 30-50% related to severe lung hypoplasia and persistent pulmonary hypertension. Prenatal evaluation with observed/expected Lung over Head Ratio (o/e LHR), liver position and total lung volume measured by magnetic resonance, have been shown to correlate with neonatal mortality . However, the preponderant factor of persistent pulmonary hypertension remains difficult to predict prenatally. In patients with isolated diaphragmatic hernia (without associated malformations or karyotype abnormalities), prognosis is evaluated indirectly on pulmonary development from pulmonary volume measurements. Apart from the most caricatural cases with extremely good or very pejorative values, for a large proportion of fetuses with diaphragmatic dome hernia the prognosis remains uncertain. The aim of the proposal is to investigate whether the analysis of the proteom of the amniotic fluid of the fetuses with CDH could give information of a prognostic character. The objective of the study is to identify, from the proteomic profile of the amniotic fluid of mothers whose fetus has CDH, prognostic markers candidates for death at 2 months of the infant. The first step is to carry out an exploratory and non-interventional study on a small sample (n = 10) of the target population. This is a preliminary step before considering, if the results are encouraging, a large-scale study from a biological collection to determine candidate proteins (new biomarkers) which relative expression levels could be used as surrogate marker of pulmonary hypoplasia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2017

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 16, 2017

Completed
2 days until next milestone

Study Start

First participant enrolled

May 18, 2017

Completed
20 days until next milestone

First Posted

Study publicly available on registry

June 7, 2017

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2019

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2019

Completed
Last Updated

July 18, 2018

Status Verified

July 1, 2018

Enrollment Period

2.1 years

First QC Date

May 16, 2017

Last Update Submit

July 17, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Neonatal death

    2 months of age

Secondary Outcomes (13)

  • Prenatal death of the fetus

    9 months

  • Neonatal death

    15 days

  • Apgar score

    5 min after birth

  • Age at surgery

    6 months of age

  • Need for a diaphragmatic prosthesis

    6 months of age

  • +8 more secondary outcomes

Study Arms (1)

1

Mothers whose fetus has CDH

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant females
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Mothers whose fetus has CDH

You may qualify if:

  • Pregnant patients for whom amniocentesis will be performed as part of the prenatal diagnosis of a diaphragmatic hernia.

You may not qualify if:

  • Refusal of patients,
  • Refusal of spouse regarding data of the future child,
  • Multiple malformations,
  • Twin pregnancy,
  • Prenatal diagnosis of an unconfirmed diaphragmatic hernia,
  • Miscarriage after amniocentesis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHU de Besançon

Besançon, 25000, France

ACTIVE NOT RECRUITING

CHU de Dijon

Dijon, 21000, France

RECRUITING

MeSH Terms

Conditions

Hernias, Diaphragmatic, Congenital

Condition Hierarchy (Ancestors)

Congenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHernia, DiaphragmaticInternal HerniaHerniaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Central Study Contacts

Frédéric Auber, Professor

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 16, 2017

First Posted

June 7, 2017

Study Start

May 18, 2017

Primary Completion

July 1, 2019

Study Completion

November 1, 2019

Last Updated

July 18, 2018

Record last verified: 2018-07

Data Sharing

IPD Sharing
Will not share

Locations